STUB1 and hematopoietic and lymphoid system neoplasm: Clinically, the high frequency of CHIP mutations in patients with hematologic neoplasms—both overt and in the state of complete remission but with the persistence of a pre-leukemic clone—raises the question of cardiovascular risk in hematologic patients.